Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Innoviva Inc's Business Segments
Innoviva Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
12
Largest Segment
GSK Long-Acting Beta2 Agonist LABA Collaboration RELVAR BREO
Total Revenue
$ 91
Regions Reported
-
Revenue Share by Reportable Segment - FY
- GSK Long-Acting Beta2 Agonist LABA Collaboration RELVAR BREO0%
- GSK Royalty Revenue64.5%
- Royalty Revenue60.7%
- GSK RELVAR BREO52%
- Net product sales45.5%
- GIAPREZA22.3%
- XACDURO19.9%
- GSK ANORO12.5%
- XERAVA2.9%
- ZEVTERA0.5%
- GSK Maximum Long-Acting Beta2 Agonist LABA Collaboration ANORO0%
- GSK Minimum Long-Acting Beta2 Agonist LABA Collaboration ANORO0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| GSK Long-Acting Beta2 Agonist LABA Collaboration RELVAR BREO | $ 3,000 | - |
| GSK Royalty Revenue | $ 59 | 64.5% |
| Royalty Revenue | $ 55 | 60.7% |
9 more segments available
Sign in to unlock the full Innoviva Inc dataset.
Revenue by Product & Service Category - FY
- Product45.5%
- GIAPREZA22.3%
- XACDURO19.9%
- XERAVA2.9%
- License and Other Revenue1.6%
- Royalty0.7%
- ZEVTERA0.5%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 41 | 45.5% |
| GIAPREZA | $ 20 | 22.3% |
| XACDURO | $ 18 | 19.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
4 more categories available
Sign in to unlock the full Innoviva Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- GSK Long-Acting Beta2 Agonist LABA Collaboration RELVAR BREO0%
- GSK Royalty Revenue64.5%
- Royalty Revenue60.7%
- GSK RELVAR BREO52%
- Net product sales45.5%
- GIAPREZA22.3%
- XACDURO19.9%
- GSK ANORO12.5%
- XERAVA2.9%
- ZEVTERA0.5%
- GSK Maximum Long-Acting Beta2 Agonist LABA Collaboration ANORO0%
- GSK Minimum Long-Acting Beta2 Agonist LABA Collaboration ANORO0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| GSK Long-Acting Beta2 Agonist LABA Collaboration RELVAR BREO | $ 3,000 | - |
| GSK Royalty Revenue | $ 59 | 64.5% |
| Royalty Revenue | $ 55 | 60.7% |
9 more segments available
Sign in to unlock the full Innoviva Inc dataset.
Description of Innoviva Inc
Innoviva Inc (formerly known as Theravance Inc) is a leading biopharmaceutical company that specializes in the development and commercialization of innovative therapies for respiratory diseases. The company was founded in 1996 and is headquartered in South San Francisco, California, with additional offices in various countries around the world.
Innoviva's mission is to improve the lives of patients suffering from respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, among others. The company's focus is on developing new and more effective ways of delivering drugs to the lungs, which can be a challenging task due to the complex structure of this organ.
One of the main products developed by Innoviva is the Ellipta inhaler, which is used for the treatment of COPD and asthma. This inhaler uses a proprietary dry powder delivery technology that makes it easier for patients to inhale the medication and ensures that the drug reaches the lungs in sufficient quantities to achieve therapeutic effect.
In addition to the Ellipta inhaler, Innoviva has a range of other respiratory drugs in its pipeline, including several in collaboration with major pharmaceutical companies such as GlaxoSmithKline and Boehringer Ingelheim. These drugs are in various stages of clinical development and are aimed at addressing the unmet needs of patients suffering from a range of respiratory diseases.
Apart from its focus on respiratory disease therapies, Innoviva also has a strong commitment to environmental sustainability. The company places great emphasis on reducing its carbon footprint and has adopted various measures to achieve this goal, such as minimizing waste generation, reducing energy consumption, and promoting the use of renewable energy sources.
Overall, Innoviva Inc has established a strong reputation for its innovative respiratory disease therapies and its commitment to environmental sustainability. The company's continued focus on R&D, collaboration with major pharmaceutical companies, and its dedication to improving patient outcomes makes it a key player in the biopharmaceutical industry.
Innoviva's mission is to improve the lives of patients suffering from respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, among others. The company's focus is on developing new and more effective ways of delivering drugs to the lungs, which can be a challenging task due to the complex structure of this organ.
One of the main products developed by Innoviva is the Ellipta inhaler, which is used for the treatment of COPD and asthma. This inhaler uses a proprietary dry powder delivery technology that makes it easier for patients to inhale the medication and ensures that the drug reaches the lungs in sufficient quantities to achieve therapeutic effect.
In addition to the Ellipta inhaler, Innoviva has a range of other respiratory drugs in its pipeline, including several in collaboration with major pharmaceutical companies such as GlaxoSmithKline and Boehringer Ingelheim. These drugs are in various stages of clinical development and are aimed at addressing the unmet needs of patients suffering from a range of respiratory diseases.
Apart from its focus on respiratory disease therapies, Innoviva also has a strong commitment to environmental sustainability. The company places great emphasis on reducing its carbon footprint and has adopted various measures to achieve this goal, such as minimizing waste generation, reducing energy consumption, and promoting the use of renewable energy sources.
Overall, Innoviva Inc has established a strong reputation for its innovative respiratory disease therapies and its commitment to environmental sustainability. The company's continued focus on R&D, collaboration with major pharmaceutical companies, and its dedication to improving patient outcomes makes it a key player in the biopharmaceutical industry.
Innoviva Inc is a dynamic biopharmaceutical company focused primarily on providing innovative therapies aimed at treating and improving the management of respiratory diseases. The company employs a multifaceted approach to address the needs of patients and healthcare providers, leveraging collaborations, a robust intellectual property portfolio, and various other business strategies. Below is an extensive look at the various segments, products, and services offered by Innoviva Inc.
1. Collaborative Developments
Innoviva engages in strategic collaborations with leading pharmaceutical companies to advance the development of novel therapies. This segment is crucial for expanding the company’s reach and capabilities in respiratory disease treatment. Notable partnerships include:
- GlaxoSmithKline (GSK): Innoviva collaborates with GSK on several respiratory products, contributing its intellectual property and expertise in the development process. This partnership facilitates the creation of new therapies, which stem from shared research and development efforts.
- Theravance Biopharma: Innovivas collaboration with this company aims to further develop innovative therapeutic solutions, leveraging combined resources for enhanced research capabilities.
Royalty Management
A significant element of Innoviva’s business model is its royalty management, which involves:
- Royalty Revenue: Innoviva receives substantial royalties from the sales of various respiratory products developed in collaboration with GSK, including:
- Relvar/Breo Ellipta: A combination therapy for asthma and chronic obstructive pulmonary disease (COPD).
- Anoro Ellipta: A once-daily inhalation treatment for COPD.
- Incruse Ellipta: A long-acting muscarinic antagonist for the treatment of COPD.
Innoviva effectively manages these royalties, ensuring timely distribution to its shareholders, thus enhancing investor confidence.
Intellectual Property Management
Innoviva boasts an extensive portfolio of patents and licenses related to respiratory disease therapies. This segment involves:
- Patent Licensing: Innoviva licenses its intellectual property to partner companies, allowing them to develop and commercialize new therapies. The management of this intellectual property is vital for fostering innovation while simultaneously generating revenue.
- Portfolio Strategy: The focus on protecting and strategically leveraging its intellectual property ensures that Innoviva remains competitive in the market.
Product Development
Innoviva is dedicated to the ongoing development of cutting-edge respiratory disease treatments. Key aspects include:
- Clinical Trials: The company is actively involved in the development of new inhaled therapies, such as those targeted for asthma treatment. These products are currently in various stages of clinical trials, showcasing Innovivas commitment to innovation and research.
- Pipeline Advancement: By focusing on bringing new products to market, Innoviva aims to address unmet medical needs in the respiratory disease sector.
Financial Management
Innoviva employs robust financial management strategies to ensure the stability and growth of the company. This segment includes:
- Investment Portfolio: Innoviva actively invests in both public and private companies within the biopharmaceutical industry, diversifying its portfolio to optimize returns.
- Financial Strategies: The company utilizes effective financial planning and analysis to monitor performance, manage expenditures, and maximize shareholder value.
Commercialization Services
Innoviva provides a suite of commercialization services to facilitate the successful launch and market penetration of respiratory therapies developed in collaboration with its partners. These services encompass:
- Market Research: Conducting comprehensive market studies to identify opportunities and potential barriers before product launch.
- Product Launch Preparation: Offering support throughout the product launch process, ensuring the transition into the market is smooth and effective.
- Market Access Support: Assisting partners in navigating regulatory landscapes and gaining market access for their respiratory products.
Investor Relations
Innoviva prioritizes the maintenance of strong relationships with its investors, which is key to sustaining investor trust and engagement. This includes:
- Transparency: The company provides regular updates on its financial and operational performance to its shareholders.
- Investor Events: Hosting conferences and events to foster relations with current and potential investors, allowing them to engage directly with executive leadership.
Conclusion
Overall, Innoviva Inc plays a vital role in the biopharmaceutical sector by providing a comprehensive range of products, services, and strategic collaborations aimed at addressing the complexities of respiratory diseases. Through its focus on collaborative development, royalty management, intellectual property, product development, financial strategies, commercialization services, and strong investor relations, Innoviva is dedicated to enhancing respiratory health outcomes while simultaneously building shareholder value.
This extensive offering positions Innoviva as a key player in the biopharmaceutical landscape, committed to producing impactful innovations in respiratory disease treatment.
1. Collaborative Developments
Innoviva engages in strategic collaborations with leading pharmaceutical companies to advance the development of novel therapies. This segment is crucial for expanding the company’s reach and capabilities in respiratory disease treatment. Notable partnerships include:
- GlaxoSmithKline (GSK): Innoviva collaborates with GSK on several respiratory products, contributing its intellectual property and expertise in the development process. This partnership facilitates the creation of new therapies, which stem from shared research and development efforts.
- Theravance Biopharma: Innovivas collaboration with this company aims to further develop innovative therapeutic solutions, leveraging combined resources for enhanced research capabilities.
Royalty Management
A significant element of Innoviva’s business model is its royalty management, which involves:
- Royalty Revenue: Innoviva receives substantial royalties from the sales of various respiratory products developed in collaboration with GSK, including:
- Relvar/Breo Ellipta: A combination therapy for asthma and chronic obstructive pulmonary disease (COPD).
- Anoro Ellipta: A once-daily inhalation treatment for COPD.
- Incruse Ellipta: A long-acting muscarinic antagonist for the treatment of COPD.
Innoviva effectively manages these royalties, ensuring timely distribution to its shareholders, thus enhancing investor confidence.
Intellectual Property Management
Innoviva boasts an extensive portfolio of patents and licenses related to respiratory disease therapies. This segment involves:
- Patent Licensing: Innoviva licenses its intellectual property to partner companies, allowing them to develop and commercialize new therapies. The management of this intellectual property is vital for fostering innovation while simultaneously generating revenue.
- Portfolio Strategy: The focus on protecting and strategically leveraging its intellectual property ensures that Innoviva remains competitive in the market.
Product Development
Innoviva is dedicated to the ongoing development of cutting-edge respiratory disease treatments. Key aspects include:
- Clinical Trials: The company is actively involved in the development of new inhaled therapies, such as those targeted for asthma treatment. These products are currently in various stages of clinical trials, showcasing Innovivas commitment to innovation and research.
- Pipeline Advancement: By focusing on bringing new products to market, Innoviva aims to address unmet medical needs in the respiratory disease sector.
Financial Management
Innoviva employs robust financial management strategies to ensure the stability and growth of the company. This segment includes:
- Investment Portfolio: Innoviva actively invests in both public and private companies within the biopharmaceutical industry, diversifying its portfolio to optimize returns.
- Financial Strategies: The company utilizes effective financial planning and analysis to monitor performance, manage expenditures, and maximize shareholder value.
Commercialization Services
Innoviva provides a suite of commercialization services to facilitate the successful launch and market penetration of respiratory therapies developed in collaboration with its partners. These services encompass:
- Market Research: Conducting comprehensive market studies to identify opportunities and potential barriers before product launch.
- Product Launch Preparation: Offering support throughout the product launch process, ensuring the transition into the market is smooth and effective.
- Market Access Support: Assisting partners in navigating regulatory landscapes and gaining market access for their respiratory products.
Investor Relations
Innoviva prioritizes the maintenance of strong relationships with its investors, which is key to sustaining investor trust and engagement. This includes:
- Transparency: The company provides regular updates on its financial and operational performance to its shareholders.
- Investor Events: Hosting conferences and events to foster relations with current and potential investors, allowing them to engage directly with executive leadership.
Conclusion
Overall, Innoviva Inc plays a vital role in the biopharmaceutical sector by providing a comprehensive range of products, services, and strategic collaborations aimed at addressing the complexities of respiratory diseases. Through its focus on collaborative development, royalty management, intellectual property, product development, financial strategies, commercialization services, and strong investor relations, Innoviva is dedicated to enhancing respiratory health outcomes while simultaneously building shareholder value.
This extensive offering positions Innoviva as a key player in the biopharmaceutical landscape, committed to producing impactful innovations in respiratory disease treatment.